Intervention Review

You have free access to this content

Opioids for neuropathic pain

  1. Ewan D McNicol1,*,
  2. Ayelet Midbari2,
  3. Elon Eisenberg3

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 29 AUG 2013

Assessed as up-to-date: 21 AUG 2013

DOI: 10.1002/14651858.CD006146.pub2


How to Cite

McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD006146. DOI: 10.1002/14651858.CD006146.pub2.

Author Information

  1. 1

    Tufts Medical Center, Departments of Anesthesiology and Pharmacy, Boston, Massachusetts, USA

  2. 2

    Institute of Pain Medicine, Pain Research Unit, Haifa, Israel

  3. 3

    Rambam Health Care Campus and the Technion-Israel Institute of Technology, Pain Research Unit, Haifa, Israel

*Ewan D McNicol, Departments of Anesthesiology and Pharmacy, Tufts Medical Center, Box #420, 800 Washington Street, Boston, Massachusetts, 02111, USA. ewan.mcnicol@tufts.edu.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 29 AUG 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Short-term Efficacy Studies: opioid vs placebo, Outcome 1 Pain intensity post-opioid/placebo.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Short-term Efficacy Studies: opioid vs placebo, Outcome 2 % Pain reduction post-opioid/placebo.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Intermediate-term Efficacy Studies: Opioid vs. Placebo, Outcome 1 Number of participants with at least 33% pain relief.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Intermediate-term Efficacy Studies: Opioid vs. Placebo, Outcome 2 Number of participants with at least 50% pain relief.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Intermediate-term Efficacy Studies: Opioid vs. Placebo, Outcome 3 Pain intensity post-opioid/placebo.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Intermediate-term Efficacy Studies: Opioid vs. Placebo, Outcome 4 Evoked pain intensity post-opioid/placebo.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Intermediate-term Efficacy Studies: Opioid vs. Placebo, Outcome 5 SF-36 Health Survey.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Intermediate-term Efficacy Studies: Opioid vs. Placebo, Outcome 6 Brief Pain Inventory: Pain Interference items.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Intermediate-term Efficacy Studies: Opioid vs. Placebo, Outcome 7 Beck Depression Inventory.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Intermediate-term Efficacy Studies: opioid vs active control, Outcome 1 Number of participants with at least 33% pain relief.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Intermediate-term Efficacy Studies: opioid vs active control, Outcome 2 Number of participants with at least 50% pain relief.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Intermediate-term Efficacy Studies: opioid vs active control, Outcome 3 Pain intensity post-opioid/active control.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Intermediate-term Efficacy Studies: opioid vs active control, Outcome 4 SF-36 Health Survey.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Intermediate-term Efficacy Studies: opioid vs active control, Outcome 5 Beck Depression Inventory.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Adverse Events from Intermediate-term Studies: opioid vs placebo, Outcome 1 Participants reporting constipation.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Adverse Events from Intermediate-term Studies: opioid vs placebo, Outcome 2 Participants reporting dizziness.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Adverse Events from Intermediate-term Studies: opioid vs placebo, Outcome 3 Participants reporting drowsiness/somnolence.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Adverse Events from Intermediate-term Studies: opioid vs placebo, Outcome 4 Participants reporting nausea.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Adverse Events from Intermediate-term Studies: opioid vs placebo, Outcome 5 Participants reporting vomiting.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Adverse Events from Intermediate-term Studies: opioid vs placebo, Outcome 6 Particpants withdrawing due to adverse events.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Adverse Events from Intermediate-term Studies: opioid vs placebo, Outcome 7 Participants withdrawing due to lack of efficacy.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Adverse Events from Intermediate-term Studies: opioid vs active control, Outcome 1 Participants reporting constipation.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Adverse Events from Intermediate-term Studies: opioid vs active control, Outcome 2 Participants reporting dizziness.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Adverse Events from Intermediate-term Studies: opioid vs active control, Outcome 3 Participants reporting drowsiness/somnolence.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Adverse Events from Intermediate-term Studies: opioid vs active control, Outcome 4 Participants reporting nausea.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Adverse Events from Intermediate-term Studies: opioid vs active control, Outcome 5 Participants reporting vomiting.
[Analysis 5.6]
Analysis 5.6. Comparison 5 Adverse Events from Intermediate-term Studies: opioid vs active control, Outcome 6 Participants withdrawing due to adverse events.
[Analysis 5.7]
Analysis 5.7. Comparison 5 Adverse Events from Intermediate-term Studies: opioid vs active control, Outcome 7 Participants withdrawing due to lack of efficacy.